Salud financiera de hoja de balance de TCI

Salud financiera controles de criterios 5/6

TCI tiene un patrimonio de accionistas total de NT$9.2B y una deuda total de NT$1.7B, lo que sitúa su ratio deuda-patrimonio en 18.5%. Sus activos y pasivos totales son NT$13.6B y NT$4.4B respectivamente. El BAIT de TCI es de NT$907.8M, por lo que su ratio de cobertura de intereses es de -32.2. Tiene efectivo e inversiones a corto plazo que ascienden a NT$5.4B.

Información clave

18.5%

Ratio deuda-patrimonio

NT$1.69b

Deuda

Ratio de cobertura de intereses	-32.2x
Efectivo	NT$5.36b
Patrimonio	NT$9.15b
Total pasivo	NT$4.42b
Activos totales	NT$13.57b

Actualizaciones recientes sobre salud financiera

We Think TCI (GTSM:8436) Can Stay On Top Of Its Debt

Jan 21

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (NT$7.5B) de 8436 superan a sus pasivos a corto plazo (NT$3.0B).

Pasivo a largo plazo: Los activos a corto plazo de 8436 (NT$7.5B) superan a sus pasivos a largo plazo (NT$1.4B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 8436 tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de 8436 ha crecido de 13.8% a 18.5% en los últimos 5 años.

Cobertura de la deuda: La deuda de 8436 está bien cubierta por el flujo de caja operativo (69.7%).

Cobertura de intereses: 8436 gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.

Salud financiera de hoja de balance de TCI

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

We Think TCI (GTSM:8436) Can Stay On Top Of Its Debt

Recent updates

Consensus EPS estimates fall by 20%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 13%

TCI Co., Ltd. Unveils Promising GLP-1 Formula Clinical Trial Results for Advanced Weight Management

TCI Co., Ltd. to Report Q2, 2024 Results on Jul 30, 2024

Dividend of NT$7.00 announced

New major risk - Revenue and earnings growth

TCI Co., Ltd. Approves the By-Election of Ching-Ting Chen as Institutional Director

Consensus EPS estimates increase by 16%

First quarter 2024 earnings: EPS exceeds analyst expectations

Now 21% overvalued

TCI Co., Ltd. Board Approves Dividend Distribution for the Year Ended December 31, 2023

TCI Co., Ltd. to Report Q1, 2024 Results on May 09, 2024

TCI Co., Ltd. to Report Q1, 2024 Results on May 09, 2024

Consensus revenue estimates fall by 12%

Full year 2023 earnings: EPS and revenues miss analyst expectations

TCI Co., Ltd., Annual General Meeting, Jun 25, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

TCI Co., Ltd. Unveils Weight Loss Formula at SupplySide West 2023

Upcoming dividend of NT$5.02 per share at 4.8% yield

TCI Co., Ltd. Announces Cash Dividend, Payable on August 22, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

TCI Introduces Vecollal

TCI Introduces Vecollal

Insufficient new directors

TCI Co., Ltd. Appoints Representative of the Legal Person as Director

Consensus EPS estimates fall by 26%

TCI Co., Ltd. Announces Cash Dividend for the Year Ended December 31, 2022

Now 22% undervalued

Now 20% undervalued

Price target increased by 11% to NT$179

Consensus forecasts updated

Price target increased to NT$177

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

TCI Co., Ltd. Announces Executive Changes

Consensus EPS estimates fall by 31%

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of NT$8.92 per share

TCI Co., Ltd. Approves Cash Dividend, Payable on August 18, 2022

Price target decreased to NT$183

TCI Co., Ltd. Appoints Members of the Risk Management Committee

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Price target decreased to NT$197

TCI Co., Ltd., Annual General Meeting, Jun 29, 2022

Price target decreased to NT$197

Consensus EPS estimates fall by 13%

Price target decreased to NT$258

Price target decreased to NT$278

Price target decreased to NT$283

Third quarter 2021 earnings released: EPS NT$4.02 (vs NT$4.23 in 3Q 2020)

Upcoming dividend of NT$8.88 per share

Second quarter 2021 earnings released: EPS NT$4.19 (vs NT$4.50 in 2Q 2020)

Investor sentiment improved over the past week

TCI Co., Ltd. (TPEX:8436) entered into a memorandum of understanding to acquire US manufacturing operations from NewAge, Inc. (NasdaqCM:NBEV) for $3.5 million.

Head of Finance Department & CFO Chia- Chi Li has left the company

Price target increased to NT$249

Price target increased to NT$240

First quarter 2021 earnings released: EPS NT$3.25 (vs NT$3.13 in 1Q 2020)

Is TCI Co., Ltd. (GTSM:8436) A Smart Choice For Dividend Investors?

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS NT$15.69 (vs NT$17.02 in FY 2019)

Analysts lower EPS estimates to NT$15.17

TCI Co., Ltd. (GTSM:8436) made an offer to acquire 30% stake in Maxigen Biotech Inc. (TSEC:1783) for approximately TWD 600 million.

Price target lowered to NT$235

Full year 2020 earnings released: EPS NT$15.69 (vs NT$17.02 in FY 2019)

Revenue and earnings miss expectations

New 90-day high: NT$221

Is TCI's (GTSM:8436) 160% Share Price Increase Well Justified?

We Think TCI (GTSM:8436) Can Stay On Top Of Its Debt

New 90-day low: NT$197

Is TCI (GTSM:8436) The Next Multi-Bagger?